Cybersecurity firm Palo Alto Networks posts Q4 FY 2023 revenue of $2bn

TAGS

Palo Alto Networks (NASDAQ: PANW), a global front-runner in cybersecurity, unveiled its fiscal results, showcasing a staggering 26% YoY growth with Q4 FY 2023 revenue touching the $2 billion mark. This is a leap from last fiscal year’s Q4 revenue of $1.6 billion.

The company’s Q4 FY 2023 GAAP net income stood at an impressive $227.7 million or $0.64 per diluted share. This is in stark contrast to the Q4 FY 2022 figure, which was pegged at $3.3 million or $0.01 per diluted share. Furthermore, the non-GAAP net income for Q4 FY 2023 was reported at $482.5 million, a significant rise from the $254.1 million in Q4 FY 2022.

See also  Accenture buys procurement spend management specialist ClearEdge Partners

Nikesh Arora, the CEO of Palo Alto Networks, attributed the company’s robust performance to the “strong execution” amidst shifting environments. He elaborated on their strategic thrust on “platformization” that garnered a favorable market reception, especially for their AI-centric security platform, XSIAM.

Cybersecurity firm Palo Alto Networks posts Q4 FY 2023 revenue of $2bn

Cybersecurity firm Palo Alto Networks posts Q4 FY 2023 revenue of $2bn. Photo courtesy of Namaste jinx/Wikimedia Commons.

Dipak Golechha, Palo Alto Networks’ CFO, highlighted the financial growth trajectory. “Despite billings not capturing the full strength this quarter, we’ve seen notable strides in our financial metamorphosis. Our year’s operating margins surged over 500 basis points, mirroring our intent on profitability,” Golechha mentioned.

See also  Native Pet launches 'The Daily', a revolutionary all-in-one dog supplement pioneering pet health

Peeking into the future, Palo Alto Networks forecasts for Q1 FY 2024 include billings in the bracket of $2.05 billion to $2.08 billion and revenue estimates ranging between $1.82 billion to $1.85 billion. Moreover, the anticipated diluted non-GAAP net income per share is projected to grow by 39%-41%. For the entire fiscal year 2024, predictions are optimistic with total billings, revenue, and diluted non-GAAP net income per share showing encouraging YoY growth percentages.

See also  Strides Pharma subsidiary gets FDA approval for Icosapent Ethyl Capsules

Fleshing out more specifics from the company’s financial records, the Q4 FY 2023 billings showed an 18% YoY growth at $3.2 billion. The full fiscal year 2023 billings augmented by 23% YoY, standing at $9.2 billion. Another noteworthy metric is the remaining performance obligation, which saw a robust 30% YoY growth, reaching $10.6 billion.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This